The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.
 
Jessica Jiyeong Lin
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim
 
Beow Y. Yeap
Consulting or Advisory Role - Abcodia (I)
 
Lorin A Ferris
No Relationships to Disclose
 
Satoshi Yoda
No Relationships to Disclose
 
Ibiayi Dagogo-Jack
No Relationships to Disclose
 
Jochen K Lennerz
No Relationships to Disclose
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Loxo; Takeda; Theravance
Research Funding - Adaptimmune (Inst); ARIAD; AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Affymetrix
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Novartis; Pfizer; Roche/Genentech